FDA approves sotatercept for treatment of pulmonary arterial hypertension in adults
The US Food and Drug Administration has approved sotatercept (Winrevair) for treatment of pulmonary arterial hypertension (PAH) in adults. Sotatercept is a novel activin signaling inhibitor which increases exercise capacity and reduce the risk of clinical worsening events for people with WHO group 1 pulmonary hypertension. WINREVAIR was previously granted Breakthrough Therapy Designation by the […]